DD128332A5 - Verfahren zur herstellung von verbindungen mit antidepressiver wirkung - Google Patents

Verfahren zur herstellung von verbindungen mit antidepressiver wirkung

Info

Publication number
DD128332A5
DD128332A5 DD7600191893A DD19189376A DD128332A5 DD 128332 A5 DD128332 A5 DD 128332A5 DD 7600191893 A DD7600191893 A DD 7600191893A DD 19189376 A DD19189376 A DD 19189376A DD 128332 A5 DD128332 A5 DD 128332A5
Authority
DD
German Democratic Republic
Prior art keywords
preparing compounds
antidepressive effect
antidepressive
effect
preparing
Prior art date
Application number
DD7600191893A
Other languages
German (de)
English (en)
Inventor
Hendricus B A Welle
Volkert Claassen
Original Assignee
Philips Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philips Nv filed Critical Philips Nv
Publication of DD128332A5 publication Critical patent/DD128332A5/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DD7600191893A 1975-03-20 1976-03-17 Verfahren zur herstellung von verbindungen mit antidepressiver wirkung DD128332A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (1)

Publication Number Publication Date
DD128332A5 true DD128332A5 (de) 1977-11-09

Family

ID=19823424

Family Applications (1)

Application Number Title Priority Date Filing Date
DD7600191893A DD128332A5 (de) 1975-03-20 1976-03-17 Verfahren zur herstellung von verbindungen mit antidepressiver wirkung

Country Status (27)

Country Link
US (1) US4085225A (OSRAM)
JP (1) JPS6026776B2 (OSRAM)
AR (2) AR211011A1 (OSRAM)
AT (1) AT340895B (OSRAM)
AU (1) AU505358B2 (OSRAM)
BE (1) BE839744A (OSRAM)
CA (1) CA1076142A (OSRAM)
CH (4) CH626057A5 (OSRAM)
DD (1) DD128332A5 (OSRAM)
DE (1) DE2610886A1 (OSRAM)
DK (1) DK144942C (OSRAM)
ES (1) ES446192A1 (OSRAM)
FI (1) FI61875C (OSRAM)
FR (1) FR2304336A1 (OSRAM)
GB (1) GB1535226A (OSRAM)
GR (1) GR60052B (OSRAM)
HU (1) HU171030B (OSRAM)
IE (1) IE43768B1 (OSRAM)
IL (1) IL49238A (OSRAM)
IT (1) IT1063064B (OSRAM)
MX (1) MX9203723A (OSRAM)
NL (1) NL7503310A (OSRAM)
PL (3) PL100614B1 (OSRAM)
SE (1) SE410312B (OSRAM)
SU (3) SU635867A3 (OSRAM)
YU (1) YU39345B (OSRAM)
ZA (1) ZA761434B (OSRAM)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
PT759299E (pt) * 1995-08-16 2000-09-29 Lilly Co Eli Potenciacao da resposta de serotonina
IN182588B (OSRAM) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (OSRAM) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation A- (BETA) -42 DECREASING MEDICINAL PRODUCTS
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
US6469064B2 (en) * 2000-04-24 2002-10-22 Aryx Therapeutics Materials and methods for the treatment of depression
NZ532033A (en) * 2001-10-12 2006-11-30 Azevan Pharmaceuticals Inc 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives as vasopressin V1a receptor antagonists
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
JP2007505097A (ja) 2003-09-12 2007-03-08 ファイザー・インク アルファ−２−デルタリガンドとセロトニン／ノルアドレナリン再取込み阻害薬を含む組合せ
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2601709C (en) 2005-03-22 2017-02-14 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids
CA2604916A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
JP2008538573A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその５−ｈｔ２ｃアゴニストとしての使用
GT200600158A (es) * 2005-04-22 2006-11-28 Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
GT200600165A (es) * 2005-04-22 2007-03-14 Derivados dihidrobenzofuranos y usos de los mismos
WO2007008758A2 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
EP1910346B1 (en) 2005-07-19 2019-02-27 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonist
NZ564789A (en) * 2005-07-22 2010-07-30 Myriad Genetics Inc High drug load formulations and dosage forms
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PE20080010A1 (es) * 2006-03-24 2008-03-10 Wyeth Corp Derivados de diazepina para el tratamiento de la depresion y composiciones farmaceuticas que los comprenden
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PT3093291T (pt) 2009-10-23 2019-07-25 Janssen Pharmaceutica Nv Octa-hidropirrolo[3,4-c]pirroles dissubstituídos como moduladores de recetores de orexina
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CA2804001C (en) 2010-07-01 2021-02-09 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
PH12013501900A1 (en) 2011-03-17 2017-08-23 Lupin Ltd Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
PT2981518T (pt) 2013-04-03 2021-06-04 Zcl Chemicals Ltd Um processo melhorado para a preparação de maleato de fluvoxamina
CA2938928C (en) 2014-02-07 2023-01-24 Mta Tamogatott Kutatocsoportok Irodaja Use of sigma-1 receptor agonist compounds
FI3122743T3 (fi) 2014-03-28 2023-03-02 Azevan Pharmaceuticals Inc Koostumuksia ja menetelmiä hermostoa rappeuttavien sairauksien hoitamiseksi
SG11201807597UA (en) 2016-03-10 2018-10-30 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
WO2018096376A1 (en) 2016-11-24 2018-05-31 Mta Támogatott Kutatócsoportok Irodája Compositions for organ preservation
US11628160B2 (en) 2017-09-15 2023-04-18 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes

Also Published As

Publication number Publication date
AR211011A1 (es) 1977-10-14
YU71476A (en) 1982-10-31
PL100614B1 (pl) 1978-10-31
AT340895B (de) 1978-01-10
CA1076142A (en) 1980-04-22
IE43768B1 (en) 1981-05-20
ATA195476A (de) 1977-05-15
ES446192A1 (es) 1977-10-01
AU1214776A (en) 1977-09-22
FR2304336A1 (fr) 1976-10-15
NL7503310A (nl) 1976-09-22
ZA761434B (en) 1977-10-26
HU171030B (hu) 1977-10-28
CH629184A5 (de) 1982-04-15
SU635867A3 (ru) 1978-11-30
IL49238A (en) 1978-08-31
CH629761A5 (de) 1982-05-14
DK144942B (da) 1982-07-12
FI760699A7 (OSRAM) 1976-09-21
PL101951B1 (pl) 1979-02-28
MX9203723A (es) 1992-07-01
IL49238A0 (en) 1976-05-31
DK115976A (da) 1976-09-21
DK144942C (da) 1982-12-06
IE43768L (en) 1976-09-20
GB1535226A (en) 1978-12-13
FR2304336B1 (OSRAM) 1979-09-28
SE7603341L (sv) 1976-09-21
FI61875B (fi) 1982-06-30
AU505358B2 (en) 1979-11-15
GR60052B (en) 1978-04-04
IT1063064B (it) 1985-02-11
YU39345B (en) 1984-10-31
PL100052B1 (pl) 1978-08-31
SU645559A3 (ru) 1979-01-30
FI61875C (fi) 1982-10-11
SU620206A3 (ru) 1978-08-15
CH629477A5 (de) 1982-04-30
JPS51125345A (en) 1976-11-01
CH626057A5 (OSRAM) 1981-10-30
US4085225A (en) 1978-04-18
AR211153A1 (es) 1977-10-31
DE2610886C2 (OSRAM) 1987-09-24
SE410312B (sv) 1979-10-08
BE839744A (fr) 1976-09-20
JPS6026776B2 (ja) 1985-06-25
DE2610886A1 (de) 1976-10-07

Similar Documents

Publication Publication Date Title
DD128332A5 (de) Verfahren zur herstellung von verbindungen mit antidepressiver wirkung
DD130857A5 (de) Verfahren zur herstellung von n-phosphonomethylglycintriestern
DD131931A5 (de) Verfahren zur herstellung von spiro-hydantoin-verbindungen
DD129330A5 (de) Verfahren zur herstellung von antitumorsubstanzen
DD127928A5 (de) Verfahren zur herstellung heterocyclischer verbindungen
DD131649A5 (de) Verfahren zur herstellung von n-(perfluoracyl)-n-phosphono-methyl-glycin-verbindungen
DD131858A5 (de) Verfahren zur herstellung von 3-chlorcephemverbindungen
DD130036A5 (de) Verfahren zur herstellung von optisch aktiven 11-desoxy-16-aryloxy-omega-tetranorprostaglandinen
DD129326A5 (de) Verfahren zur herstellung von 1,4-diphenyl-3-pyrazolin-5-onen
AT341668B (de) Verfahren zur herstellung von 7-aminocephemverbindungen
AT342191B (de) Verfahren zur herstellung von arzneimittelkombinationen
AT333305B (de) Verfahren zur herstellung von phosphonothioureidoverbindungen
DD128330A5 (de) Verfahren zur herstellung von verbindungen mit antidepressiver wirkung
DD131562A5 (de) Verfahren zur herstellung von 5-pregnen-derivaten
DD122961A5 (de) Verfahren zur herstellung von diphenylaether-derivaten
AT352914B (de) Verfahren zur herstellung von polyen- verbindungen
DD122976A5 (de) Verfahren zur herstellung von pyridoepoxyaethanen
DD122964A5 (de) Verfahren zur herstellung von prostensaeurederivaten
DD128329A5 (de) Verfahren zur herstellung von verbindungen mit antidepressiver wirkung
AT339268B (de) Verfahren zur herstellung von acetoxybutanolen
DD133327A5 (de) Verfahren zur herstellung von organischen verbindungen
AT350199B (de) Verfahren zur herstellung von 17-monoestern von 17alfa,21-dihydroxysteroiden
DD133147A5 (de) Verfahren zur herstellung antihelmintischer verbindungen
AT338775B (de) Verfahren zur herstellung von 4-oxa-5-hydroxypolycycloalken-3-onen
DD128709A5 (de) Verfahren zur herstellung von dekahydrochinolinderivaten